BioMarin Pharm: License For Naglazyme Submitted In Japan (Japan)
This article was originally published in PharmAsia News
Executive Summary
BioMarin Pharmaceutical Inc. said Anges MG Inc. submitted a biologics license application to the Japanese Ministry of Health, Labour, and Welfare for its Naglazyme drug to treat Maroteaux-Lamy syndrome. The biopharmaceutical company established its marketing and distribution agreement with AnGes in December 2006. Final results for a Phase III trial of BioMarin's Kuvan drug were published in The Lancet. The study suggested that treatment with Kuvan resulted in significant reductions in blood Phe levels in some phenylketonuria patients. (Click here for more - May Require Paid Subscription